• Je něco špatně v tomto záznamu ?

Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience

V. Sandecka, Z. Adam, M. Krejci, M. Stork, Z. Rehak, R. Koukalova, S. Sevcikova, L. Brozova, Z. Kral, J. Mayer, L. Pour,

. 2020 ; 67 (4) : 939-945. [pub] 20200623

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028065

Monoclonal gammopathy of undetermined significance (MGUS) is a known precursor of more serious cancers, such as multiple myeloma (MM), Waldenström macroglobulinemia (MW) and other lymphoproliferative disorders. Using 18F-FDG PET/CT, we aimed to evaluate its benefit in early detection of various accompanying disorders and illnesses in MGUS patients. We prospectively analyzed the diagnostic relevance of 18F-FDG PET/CT in 390 newly diagnosed MGUS patients. On 18F-FDG PET/CT scans, the presence of focal or diffuse areas of detectable increased tracer uptake was recorded in 37 (9.5%) MGUS patients. The most frequent pathology was lymphadenopathy (3.8%), followed by thyroid diseases (2.1%), rheumatic diseases (1.8%), and other solid malignancies (1.5%). These results have major implications for confirmed associations of MGUS with numerous malignant and non-malignant disorders. We believe that 18F-FDG PET/CT imaging in newly diagnosed MGUS patients may be useful in early detection of other serious pathologies, not only in predicting progression of MGUS to active MM, and should be strongly recommended if available.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028065
003      
CZ-PrNML
005      
20210114152914.0
007      
ta
008      
210105s2020 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2020_191104N1137 $2 doi
035    __
$a (PubMed)32567936
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Sandecka, V $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic.
245    10
$a Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience / $c V. Sandecka, Z. Adam, M. Krejci, M. Stork, Z. Rehak, R. Koukalova, S. Sevcikova, L. Brozova, Z. Kral, J. Mayer, L. Pour,
520    9_
$a Monoclonal gammopathy of undetermined significance (MGUS) is a known precursor of more serious cancers, such as multiple myeloma (MM), Waldenström macroglobulinemia (MW) and other lymphoproliferative disorders. Using 18F-FDG PET/CT, we aimed to evaluate its benefit in early detection of various accompanying disorders and illnesses in MGUS patients. We prospectively analyzed the diagnostic relevance of 18F-FDG PET/CT in 390 newly diagnosed MGUS patients. On 18F-FDG PET/CT scans, the presence of focal or diffuse areas of detectable increased tracer uptake was recorded in 37 (9.5%) MGUS patients. The most frequent pathology was lymphadenopathy (3.8%), followed by thyroid diseases (2.1%), rheumatic diseases (1.8%), and other solid malignancies (1.5%). These results have major implications for confirmed associations of MGUS with numerous malignant and non-malignant disorders. We believe that 18F-FDG PET/CT imaging in newly diagnosed MGUS patients may be useful in early detection of other serious pathologies, not only in predicting progression of MGUS to active MM, and should be strongly recommended if available.
650    _2
$a dospělí $7 D000328
650    _2
$a fluorodeoxyglukosa F18 $7 D019788
650    _2
$a lidé $7 D006801
650    12
$a monoklonální gamapatie nejasného významu $x diagnostické zobrazování $7 D008998
650    12
$a mnohočetný myelom $x diagnostické zobrazování $7 D009101
650    _2
$a PET/CT $7 D000072078
650    _2
$a pozitronová emisní tomografie $7 D049268
655    _2
$a časopisecké články $7 D016428
700    1_
$a Adam, Z $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic.
700    1_
$a Krejci, M $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic.
700    1_
$a Stork, M $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic.
700    1_
$a Rehak, Z $u Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Koukalova, R $u Department of Nuclear Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Sevcikova, S $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Brozova, L $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Kral, Z $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic.
700    1_
$a Mayer, J $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic.
700    1_
$a Pour, L $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 67, č. 4 (2020), s. 939-945
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32567936 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152912 $b ABA008
999    __
$a ok $b bmc $g 1608400 $s 1119245
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 67 $c 4 $d 939-945 $e 20200623 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace